Roche's Avastin Rejected by U.K. Agency for Colorectal Cancer

Published: Nov 15, 2010

Bloomberg -- Roche Holding AG’s Avastin failed to win the backing of the U.K. National Institute for Health and Clinical Excellence for use in combination with chemotherapy against colorectal cancer that has spread.

Back to news